Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHA:600572)
China flag China · Delayed Price · Currency is CNY
4.480
0.00 (0.00%)
Feb 3, 2026, 3:00 PM CST

SHA:600572 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Revenue
6,4896,4266,6525,9456,5315,863
Other Revenue
89.0289.0280.5954.9537.6746.16
6,5786,5156,7336,0006,5685,909
Revenue Growth (YoY)
1.80%-3.23%12.21%-8.64%11.15%-12.70%
Cost of Revenue
3,1273,1012,8352,4702,6262,088
Gross Profit
3,4503,4143,8973,5313,9423,821
Selling, General & Admin
2,5312,4802,8322,5812,9642,967
Research & Development
275.53300.02298.09195.72202.49184.99
Other Operating Expenses
129.9652.8-38.4962.9964.6575.31
Operating Expenses
2,9362,8343,0932,8403,2683,239
Operating Income
513.97579.93804.32690.41674.18581.56
Interest Expense
-7.39-20.79-36.4-49.47-73.22-123.65
Interest & Investment Income
82.53101.92135.2789.352,611302.83
Currency Exchange Gain (Loss)
5.225.223.09-1.110.06-6.16
Other Non Operating Income (Expenses)
-3.77-1.06-21.98-3.76-9.31-1.09
EBT Excluding Unusual Items
590.56665.22884.3725.423,203753.5
Impairment of Goodwill
------52.99
Gain (Loss) on Sale of Investments
121.3930.27-146.04-238.23-714.6934.63
Gain (Loss) on Sale of Assets
5.4920.5535.6836.0242.22-4.86
Asset Writedown
-5.85-5.46-7.18-1.84-95.71-48.15
Other Unusual Items
117.469.360.9368.6492.5583.52
Pretax Income
828.98779.94767.69590.012,527765.65
Income Tax Expense
120.63121.5992.97129.89391.13216.45
Earnings From Continuing Operations
708.35658.35674.72460.122,136549.2
Minority Interest in Earnings
-20.36-35.94-83.15-102-118.31-95.9
Net Income
687.99622.42591.57358.122,017453.3
Net Income to Common
687.99622.42591.57358.122,017453.3
Net Income Growth
41.33%5.21%65.19%-82.25%345.06%-
Shares Outstanding (Basic)
2,5182,5272,5722,5582,5862,518
Shares Outstanding (Diluted)
2,5212,5312,5722,5582,5862,518
Shares Change (YoY)
-0.94%-1.59%0.55%-1.10%2.71%-5.28%
EPS (Basic)
0.270.250.230.140.780.18
EPS (Diluted)
0.270.250.230.140.780.18
EPS Growth
42.85%7.09%64.29%-82.05%333.33%-
Free Cash Flow
861.44721.9689.5863.73309.8789.3
Free Cash Flow Per Share
0.340.280.270.340.120.31
Dividend Per Share
0.1500.1500.2000.1500.160-
Dividend Growth
-25.00%-25.00%33.33%-6.25%--
Gross Margin
52.46%52.41%57.88%58.84%60.02%64.66%
Operating Margin
7.81%8.90%11.95%11.51%10.26%9.84%
Profit Margin
10.46%9.55%8.79%5.97%30.72%7.67%
Free Cash Flow Margin
13.10%11.08%10.24%14.39%4.72%13.36%
EBITDA
854.89913.751,129963.34956.65847.64
EBITDA Margin
13.00%14.03%16.76%16.05%14.56%14.34%
D&A For EBITDA
340.92333.82324.35272.93282.47266.07
EBIT
513.97579.93804.32690.41674.18581.56
EBIT Margin
7.81%8.90%11.95%11.51%10.26%9.84%
Effective Tax Rate
14.55%15.59%12.11%22.02%15.48%28.27%
Revenue as Reported
6,5786,5156,7336,0006,5685,909
Source: S&P Global Market Intelligence. Standard template. Financial Sources.